» Articles » PMID: 33894002

A and A Adenosine Receptors Play a Protective Role to Reduce Prevalence of Autoimmunity Following Tissue Damage

Overview
Date 2021 Apr 24
PMID 33894002
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Adenosine is a potent modulator that has a tremendous effect on the immune system. Adenosine affects T cell activity, and is necessary in maintaining the T helper/regulatory T cell (T ) ratio. Adenosine signalling is also involved in activating neutrophils and the formation of neutrophil extracellular traps (NETs), which has been linked to autoimmune disorders. Therefore, adenosine, through its receptors, is extremely important in maintaining homeostasis and involved in the development of autoimmune diseases. In this study, we aim to evaluate the role of adenosine A and A receptors in involvement of autoimmune diseases. We studied adenosine regulation by NETosis in vitro, and used two murine models of autoimmune diseases: type I diabetes mellitus (T1DM) induced by low-dose streptozotocin and pristane-induced systemic lupus erythematosus (SLE). We have found that A R enhances and A R suppresses NETosis. In addition, in both models, A R-knock-out (KO) mice were predisposed to the development of autoimmunity. In the SLE model in wild-type (WT) mice we observed a decline of A R mRNA levels 6 h after pristane injection that was parallel to lymphocyte reduction. Following pristane, 43% of A R-KO mice suffered from lupus-like disease while WT mice remained without any sign of disease at 36 weeks. In WT mice, at 10 days A R mRNA levels were significantly higher compared to A1R-KO mice. Similar to SLE, in the T1DM model the presence of A R and A R was protective. Our data suggest that, in autoimmune diseases, the acute elimination of lymphocytes and reduction of DNA release due to NETosis depends upon A R desensitization and long-term suppression of A R.

Citing Articles

Role of adenosine A2a receptor in cancers and autoimmune diseases.

Ye H, Zhao J, Xu X, Zhang D, Shen H, Wang S Immun Inflamm Dis. 2023; 11(4):e826.

PMID: 37102661 PMC: 10091380. DOI: 10.1002/iid3.826.


Adenosine and Inflammation: Here, There and Everywhere.

Pasquini S, Contri C, Borea P, Vincenzi F, Varani K Int J Mol Sci. 2021; 22(14).

PMID: 34299305 PMC: 8304851. DOI: 10.3390/ijms22147685.

References
1.
Deaglio S, Dwyer K, Gao W, Friedman D, Usheva A, Erat A . Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204(6):1257-65. PMC: 2118603. DOI: 10.1084/jem.20062512. View

2.
Ali R, Gandhi A, Meng H, Yalavarthi S, Vreede A, Estes S . Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. Nat Commun. 2019; 10(1):1916. PMC: 6478874. DOI: 10.1038/s41467-019-09801-x. View

3.
Antonioli L, Fornai M, Blandizzi C, Pacher P, Hasko G . Adenosine signaling and the immune system: When a lot could be too much. Immunol Lett. 2018; 205:9-15. DOI: 10.1016/j.imlet.2018.04.006. View

4.
Vuerich M, Harshe R, Robson S, Longhi M . Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity. Int J Mol Sci. 2019; 20(3). PMC: 6386992. DOI: 10.3390/ijms20030528. View

5.
Schuler P, Saze Z, Hong C, MULLER L, Gillespie D, Cheng D . Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol. 2014; 177(2):531-43. PMC: 4226604. DOI: 10.1111/cei.12354. View